All In Biotech

Drug Trial Radar · NCT06855069

HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 468 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

468

Planned (sponsor's estimate)

Start

Mar 13, 2025

Primary completion

Mar 7, 2027

Study completion Mar 7, 2029

Sponsor

Lead sponsor
Hansoh BioMedical R&D CompanyIndustry
Sponsor type
Industry
First posted
Mar 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of HS-20089 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.

Conditions

  • Ovarian Cancer

Interventions

  • HS-20089Drug

    HS-20089 dose 1

  • PaclitaxelDrug

    Paclitaxel dose 2

  • DoxorubicinDrug

    Doxorubicin dose 3

  • TopotecanDrug

    Topotecan dose 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS) assessed by Blinded Independ Review Committee (BIRC) as per RECIST 1.1Time frame: Screening up to study completion, an average of 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.